Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Value Market Research | PRODUCT CODE: 1959197

Cover Image

PUBLISHER: Value Market Research | PRODUCT CODE: 1959197

Global Prediabetes Market Size, Share, Trends & Growth Analysis Report 2026-2034

PUBLISHED:
PAGES: 114 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3920
PDF & Excel (10-user License)
USD 4730
PDF & Excel (Corporate User License)
USD 7430

Add to Cart

The Prediabetes Market size is expected to reach USD 506.93 Million in 2034 from USD 259.37 Million (2025) growing at a CAGR of 7.73% during 2026-2034.

The global prediabetes market is poised for significant growth, driven by the increasing prevalence of prediabetes and the rising awareness of its health implications. Prediabetes, characterized by elevated blood sugar levels that are not yet high enough to be classified as diabetes, affects millions of individuals worldwide. As healthcare providers and patients recognize the importance of early intervention to prevent the progression to type 2 diabetes, the demand for screening, diagnostic tools, and management solutions for prediabetes is expected to rise substantially, fostering innovation and investment in this critical market.

Moreover, advancements in digital health technologies and personalized medicine are anticipated to further boost the prediabetes market. The development of mobile health applications, wearable devices, and telehealth platforms enables individuals to monitor their blood sugar levels, track lifestyle changes, and receive personalized guidance from healthcare professionals. Additionally, the growing emphasis on lifestyle modification programs, including dietary changes and physical activity, is driving the demand for comprehensive management solutions that empower individuals to take control of their health. As the healthcare landscape continues to evolve, the market for prediabetes solutions is likely to witness a surge in demand for innovative products and services that cater to diverse patient needs.

In addition, the increasing focus on regulatory compliance and public health initiatives is expected to shape the future of the prediabetes market. As governments and health organizations implement programs aimed at raising awareness and promoting preventive measures, the demand for prediabetes screening and management solutions will continue to rise. Collaborative efforts between healthcare providers, technology developers, and regulatory bodies will be essential in driving these advancements, ensuring that the prediabetes market remains responsive to the evolving needs of patients and healthcare systems.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • Biguanide
  • Thiazolidinediones
  • Glucagon-Like Peptide-1 Agonists (GLP-1)
  • SGLT2 Inhibitors
  • DPP-4 Inhibitors
  • Others

By Age Group

  • Children (12-18 Years)
  • Adults (18-49)
  • Elderly (50+)

COMPANIES PROFILED

  • Novo Nordisk, Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, Aphaia Pharma, AstraZeneca, BristolMyers Squibb

We can customise the report as per your requriements

Product Code: VMR112114025

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREDIABETES MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Biguanide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Thiazolidinediones Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Glucagon-Like Peptide-1 Agonists (GLP-1) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. SGLT2 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. DPP-4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREDIABETES MARKET: BY AGE GROUP 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Age Group
  • 5.2. Children (12-18 Years) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Adults (18-49) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Elderly (50+) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREDIABETES MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Drug Class
    • 6.2.2 By Age Group
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Drug Class
    • 6.3.2 By Age Group
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Drug Class
    • 6.4.2 By Age Group
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Drug Class
    • 6.5.2 By Age Group
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Drug Class
    • 6.6.2 By Age Group
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PREDIABETES INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Novo Nordisk
    • 8.2.2 Valbiotis
    • 8.2.3 Resverlogix
    • 8.2.4 Caelus Health
    • 8.2.5 SciMar
    • 8.2.6 Boston Therapeutics
    • 8.2.7 Aphaia Pharma
    • 8.2.8 AstraZeneca
    • 8.2.9 Bristol-Myers Squibb
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!